Outlook TherapeuticsOTLK
13F holders, Q2 2024 (June 30)1holders −2
0new positions
2sold out
$7.38avg. 13F price*
At the end of Q2 2024, 1 institutions reported holding Outlook Therapeutics Inc. (OTLK) in their 13F filings, down 2 from Q1 2024. 0 opened new positions and 2 sold out. The largest holder was Rosalind Advisors, Inc. ($3.3M).
- Company
- Outlook Therapeutics Inc.
- CUSIP
- 69012T206
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $4K |
All 13F filers, Q1 2024 → Q2 2024: 138,225 shares bought and 3,863 shares sold, net +134,362 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Rosalind Advisors, Inc. | 2.63% | Add +44.3% | 450,000 | $3.3M |
"% of holder's portfolio" is OTLK's weight in each manager's 13F, not the share of Outlook Therapeutics Inc. the manager owns.